Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) has received an average rating of “Buy” from the eight ratings firms that are covering the firm, MarketBeat.com reports. Two analysts have rated the stock with a sell rating and six have issued a buy rating on the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $36.40.
A number of equities research analysts have commented on BHVN shares. Piper Jaffray Companies set a $48.00 price objective on Biohaven Pharmaceutical and gave the stock a “buy” rating in a research report on Monday, December 11th. Needham & Company LLC restated a “buy” rating and set a $36.00 price objective on shares of Biohaven Pharmaceutical in a research report on Wednesday, November 15th. BidaskClub lowered Biohaven Pharmaceutical from a “sell” rating to a “strong sell” rating in a research report on Tuesday, November 14th. Canaccord Genuity started coverage on Biohaven Pharmaceutical in a research report on Friday, December 15th. They set a “buy” rating and a $30.00 price objective for the company. Finally, Zacks Investment Research upgraded Biohaven Pharmaceutical from a “hold” rating to a “buy” rating and set a $25.00 price objective for the company in a research report on Monday, December 4th.
In other news, Director Declan Doogan sold 121,942 shares of Biohaven Pharmaceutical stock in a transaction dated Friday, January 12th. The stock was sold at an average price of $26.78, for a total transaction of $3,265,606.76. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Gregory Bailey sold 20,600 shares of Biohaven Pharmaceutical stock in a transaction dated Monday, November 27th. The shares were sold at an average price of $25.92, for a total value of $533,952.00. Following the sale, the director now owns 1,289,699 shares of the company’s stock, valued at $33,428,998.08. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 1,041,569 shares of company stock valued at $28,816,901.
Biohaven Pharmaceutical (NYSE:BHVN) opened at $32.49 on Wednesday. The firm has a market capitalization of $1,170.00 and a PE ratio of -6.22. Biohaven Pharmaceutical has a 12 month low of $17.00 and a 12 month high of $39.51.
Biohaven Pharmaceutical (NYSE:BHVN) last announced its quarterly earnings data on Tuesday, November 14th. The company reported ($1.19) EPS for the quarter, topping the Zacks’ consensus estimate of ($1.22) by $0.03. sell-side analysts anticipate that Biohaven Pharmaceutical will post -6.4 earnings per share for the current year.
TRADEMARK VIOLATION WARNING: “Biohaven Pharmaceutical Holding Co Ltd (BHVN) Receives Consensus Recommendation of “Buy” from Brokerages” was first published by American Banking News and is the property of of American Banking News. If you are accessing this article on another domain, it was illegally copied and republished in violation of United States & international copyright and trademark legislation. The correct version of this article can be read at https://www.americanbankingnews.com/2018/02/07/biohaven-pharmaceutical-holding-co-ltd-bhvn-receives-consensus-recommendation-of-buy-from-brokerages.html.
About Biohaven Pharmaceutical
Biohaven Pharmaceutical Holding Company Ltd. is a United States-based biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. It has a portfolio of multiple late-stage drug candidates.
Receive News & Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.